Some studies have suggested that in patients with CRC-PM, the rates of KRAS and BRAF mutations are similar to those of primary CRC [26,27,28,29,30], but others have found that PM has a higher rate of BRAF mutations (25–36%) than primary CRC (5–10%) [31,32]. This evidence concerns the gene KRAS and colorectal carcinoma.